To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD).

Conjunctival myxoma is a rare benign tumor that accounts for <0.001% of conjunctival lesions.1 It is important to recognize this entity, because it might be associated with cardiac myxoma, which can be life threatening.2 Based on a series of 4 cases, Herwig et al2 recently described the new entity, the conjunctival stromal tumor (COST), with its name deduced from the well-known gastrointestinal stromal tumor, showing a partially similar immunomarker profile. Positive markers for COST include CD34, vimentin, and partially for CD68; negative markers include S100 and smooth muscle actin.

To describe the association between morphologic features on fundus photography (FP), fluorescein angiography (FA), and optical coherence tomography (OCT) and visual acuity (VA) in the second year of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

To investigate the efficacy of the Amsler grid test in detecting central visual field (VF) defects in glaucoma.

Both vascular endothelial growth factor inhibitors and steroids given intravitreally have demonstrated superior visual acuity (VA) benefits to laser and/or sham for center-involving diabetic macular edema (DME).1

To describe the associations of physical and demographic factors with Goldmann-correlated intraocular pressure (IOPg) and corneal-compensated intraocular pressure (IOPcc) in a British cohort.